HIV-1-INFECTION

This study compared two HIV treatment approaches in people who had never taken HIV drugs before. One group started with a three-drug combo for 16 weeks, then switched to a two-drug combo. The other group took a two-drug combo from the start. The goal was to see if the first appro…

This study tested whether a once-weekly oral combination of two experimental drugs (lepetegravir and lenacapavir pacfosacil) could control HIV as well as the standard daily pill Biktarvy. It enrolled 73 people newly diagnosed with HIV-1 who had never taken HIV medication. The stu…

This study looked at whether different medications for opioid use disorder (methadone, buprenorphine/naloxone, or naltrexone) could reduce immune system inflammation in people with HIV. Researchers measured changes in blood markers of immune activation over 24 weeks. The trial wa…

This study tested whether HIV patients who already had the virus under control could switch to weekly injections of leronlimab (PRO 140) instead of their usual daily pills. The goal was to see if the drug alone could keep the virus suppressed safely over a longer period. The tria…

This was a small, early-phase study testing an experimental HIV drug called GS-1219 in just 4 people living with HIV-1. The goal was to check the drug's safety and how well it fights the virus. The study was terminated early, so results are very limited.

This study tested whether a group therapy program, led by trained youth leaders, could improve mental health and help young people with HIV stick to their medication. About 484 youth in low-resource settings took part. The program used trauma-informed counseling adapted to local …

This study compared signs of aging in 123 HIV-infected adults to the general population. Researchers measured bone density, muscle strength, skin changes, and thinking abilities. The goal was to understand if HIV speeds up aging in these areas. No new treatment was tested; it was…